Treatment guidelines for Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were published in 2023 and 2021, respectively. Dr. Mamatha Pasnoor, Professor of Neurology at the University of Kansas Medical Center and member of the Global Medical Advisory Board, will discuss the GBS and CIDP diagnosis and treatment guidelines that inform clinical decision-making. We’ll explore how the guidelines were developed, how healthcare providers use them, and highlight key treatment recommendations. MMN patients and their families may still find value in learning how treatment guidelines are created and applied across related conditions.
Other Articles You May Like
LONDC & ANF Launch “Why Behind Your Weakness” Campaign
We’re excited to announce that the Late-Onset Neuromuscular Disease Consortium (LONDC) and ANF launched the…
Speaker Series: What is the Nervous System
The nervous system plays a vital role in how your body moves, feels, and functions,…
Global Collaboration Sparks Policy Change in Turkey
In early 2025, the Foundation’s International team was presented with an evolving situation in Turkey…